How long can one live with high-grade urothelial cancer?

High-grade urothelial carcinomas generally produce greater internality and higher switching rates. If patients are discovered and receive timely treatment during the interval, their annual survival rate is relatively high. In comparison, especially after complete transurethral vaginal resection (TURBT) adjuvant treatment, the tumor may reach 50%-70%. However, the risk of high-grade cancer remains increased and requires regular monitoring and follow-up treatment.

When high-grade urothelial cancer extends into the muscle layer of the bladder, its spine deteriorates significantly. For patients who undergo radical cystectomy combined with neoadjuvant chemotherapy, the 5annual rate is approximately 30%-50%. The effectiveness of treatment depends on complete removal of the cancer, the patient's physical condition, and whether he or she receives subsequent adjuvant therapy. Some patients may require vaginal replacement surgery to maintain quality of life.

For metastatic high-grade urothelial carcinoma, the goals of treatment are usually to prolong survival and improve quality of life. The median survival of untreated patients is usually less than 6 months. With systemic chemotherapy (such as cisplatin combination therapy) or immunotherapy (such as PD-1/PD-L1), the median survival can be extended to 12-18 months. Some patients who are highly sensitive to treatment may survive for more than 2 years, but the likelihood of complete cure is extremely low.

In recent years, the emergence of immunotherapy and suppressive therapy has provided new treatment options for patients with high-grade urothelial cancer. For example, drugs such as atizol anemia and pembrolizumab have shown potential for long-term survival in some patients. In addition, FGFRmutant drugs (such as erdafitinib) also bring hope to specific patient groups. As more new treatments are developed, patients' survival times may be further extended in the future.

(Click to view an introduction to drugs for the treatment of urothelial cancer.)

xa0

Reference materials

American Cancer Society (American Cancer Society):https ://www .cancer .org